A PhD, four papers, and a placebo-controlled trial into one of medicine's harder problems.

I began with a systematic review of everything published on the safety and effectiveness of medicinal cannabis in fibromyalgia. The honest answer was: promising, and nowhere near good enough. Small studies. Inconsistent outcome measures. Not enough placebo control.

Next, a systematic review and meta-analysis, pooling every available measurement of endocannabinoids and related compounds in the blood and tissue of people with fibromyalgia and chronic widespread pain.

We found consistent differences. Several endocannabinoid-related compounds were elevated compared with healthy controls, which supports the idea that this system is dysregulated in these conditions rather than functioning normally.

That matters more than it might sound. It moves fibromyalgia a step further from “we cannot find anything wrong with you” and a step closer to “here is a system that appears to be behaving differently.”

We conducted a randomised, double-blind, placebo-controlled pilot trial of a balanced 1:1 THC/CBD cannabis oil in adults with fibromyalgia, under ethics approval from Southern Cross University and Griffith University.

We measured pain, sleep, fatigue, function and quality of life using validated instruments, alongside safety monitoring and individualised dose titration. Nobody, including me, knew who was receiving the cannabis oil and who was receiving the placebo until the data were locked.

Twenty-four adults with fibromyalgia, all women in this sample, were randomised, and 22 completed the trial. Recruitment did not reach the planned target, largely because of travel demands and concerns about THC driving laws, but retention was high at 91.7%, and adherence was excellent, with every participant taking at least 90% of prescribed doses. In this small sample, the oil appeared generally well tolerated: most adverse events were mild, and no serious adverse events were observed.

Among participants with valid symptom data, secondary outcomes suggested a preliminary signal for pain, sleep and overall fibromyalgia impact. At week 12, 70% of the cannabis group reported at least 30% pain reduction compared with 40% of placebo, and clinically meaningful FIQR improvement occurred in 40% versus 10%. But fatigue and mood outcomes were less clear, the study was not powered to prove efficacy, and blinding was imperfect.

A companion mechanistic paper asked a different question: if symptoms changed, could we see corresponding changes in blood markers related to the endocannabinoid system?

This analysis measured fasting morning blood levels of three endocannabinoid-related N-acylethanolamines, PEA, OEA and SEA, over the 16-week dosing period. These markers remained stable in both the cannabis and placebo groups, with no significant treatment-related changes. AEA and 2-AG could not be reliably measured with the assay used and were excluded from analysis.

In plain language, the preliminary symptom signals seen in the pilot trial were not mirrored by sustained changes in these peripheral blood markers. That suggests these particular markers may have limited use for monitoring response to this formulation, and that future research may need to look more closely at timing, more sensitive assays and central nervous system mechanisms.

All of it came together as The role of the endocannabinoid system and medicinal cannabis in fibromyalgia syndrome, a Doctor of Philosophy in Health Science from Southern Cross University.

It is freely available to read in full.